Resminostat
Resminostat is an oral drug of the HDAC inhibitor class, proposed for advanced mycosis fungoides and Sézary syndrome, two cutaneous T-cell lymphomas. Europe's medicines committee said no to it in May 2025, so it is not authorised.
Overview
Resminostat (Kinselby, applicant 4SC AG, orphan designation) was proposed for the treatment of patients with advanced-stage mycosis fungoides and Sézary syndrome. The CHMP adopted its opinion on 22 May 2025 and the opinion status on the EMA product page is negative, so there is no EU marketing authorisation. The active substance is resminostat mesilate; the EMA lists the therapeutic area as mycosis fungoides. The corpus's approved HDAC inhibitors in cutaneous T-cell lymphoma are romidepsin and vorinostat (target page `hdac`).
- Histones
- Marks read / written / erased
Oral histone deacetylase inhibitor proposed for advanced-stage mycosis fungoides and Sézary syndrome; the EMA's committee adopted a negative opinion on the marketing application (EMA product page). Connects to Histone deacetylases (HDAC).
1.Resminostat slips into a pocket on Histone deacetylases (HDAC).
Compare all products across the US, EU, UK, Japan, China and Australia →
- 22 May 2025Complete response letterEU
CHMP negative opinion on Kinselby (resminostat) for advanced mycosis fungoides and Sézary syndrome source
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Resminostat" OR ABSTRACT:"Resminostat" OR TITLE:"Kinselby" OR ABSTRACT:"Kinselby" OR TITLE:"resminostat" OR ABSTRACT:"resminostat" OR TITLE:"resminostat mesilate" OR ABSTRACT:"resminostat mesilate" OR TITLE:"4SC-201" OR ABSTRACT:"4SC-201") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Resminostat, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentVorinostat
Shares Romidepsin, Histone deacetylases (HDAC), Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- TreatmentBelinostat
Shares Histone deacetylases (HDAC), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- TargetTET2
Shares Romidepsin, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- RoadmapEpigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome
Shares Romidepsin, Histone deacetylases (HDAC), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).